# Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

> **NCT01068327** · PHASE1 · COMPLETED · sponsor: **University of Nebraska** · enrollment: 46 (actual)

## Conditions studied

- Adenocarcinoma of the Pancreas
- Stage III Pancreatic Cancer

## Interventions

- **DRUG:** gemcitabine hydrochloride
- **DRUG:** leucovorin calcium
- **DRUG:** fluorouracil
- **DRUG:** nelfinavir mesylate
- **RADIATION:** stereotactic body radiation therapy
- **RADIATION:** hypofractionated radiation therapy
- **PROCEDURE:** therapeutic conventional surgery

## Key facts

- **NCT ID:** NCT01068327
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11-05
- **Primary completion:** 2013-08-01
- **Final completion:** 2015-02-01
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2023-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01068327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01068327, "Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01068327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*